AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Check for active clinical trials using this agent. (NCI Thesaurus)
Contact：Wuhan Sun-shine Bio-technologyCorporation Limited Add: Building C16, No.388 Gaoxin 2Road, East Lake Hi-tech Development Zone, Wuhan 430200, China Tel: +86-27-65522452 QQ：1973737790 Web: http://www.sun-shinechem.com
| 
